HMGCS2 and apocrine sweat gland neoplasm: Thus, HMGCS2+/AR+/ER-/PR- profile exhibited a significantly higher sensitivity as compared with the AR+/ER-/PR- phenotype, which only provides a sensitivity of 54,17% for apocrine tumors.